On Monday, Shares of Citigroup Inc (NYSE:C), gain 0.30% to $57.76.
Citigroup has agreed to pay nearly $180 million to settle charges that two of the banks auxiliaries defrauded investors by claiming hedge funds that collapsed during the financial crisis were safe investments. Fortune report
The Securities and Exchange Commission said that Citigroup Global Markets Inc and Citigroup Alternative Investments LLC are settling without admitting or denying the charges, and that the funds will bear all of the costs for distributing the money to harmed investors. Reuters
The SEC said that the bank’s two units made “false and misleading” statements to investors in both the ASTA/MAT fund and the Falcon fund, which collectively raised nearly $3 billion in capital before collapsing. Reuters
Citigroup Inc., a diversified financial services holding company, provides various financial products and services for consumers, corporations, governments, and institutions worldwide. The company operates through two segments, Global Consumer Banking (GCB) and Institutional Clients Group (ICG).
Shares of Office Depot Inc (NASDAQ:ODP), declined -0.64% to $7.71, during its last trading session.
Office Depot Inc, a leading global provider of office products, services and solutions and parent company of Office Depot and OfficeMax, has the school supplies students, parents and teachers need to ‘Gear Up for School’ this back-to-school season. A recent online survey commissioned by Office Depot found that the majority of college students and their parents (94%) agree that the right school supplies set students up for a successful school year and can give them a boost of confidence, a sense of accomplishment, and even feelings of excitement.
“At Office Depot, we understand and recognize the importance of that new gear feeling,” said Tim Rea, executive vice president and chief marketing officer for Office Depot, Inc. “With that in mind, we strive to provide the best back-to-school gear to assist everyone reach their peak performance.”
Office Depot, Inc., together with its auxiliaries, supplies office products and services. The company’s North American Retail division sells an assortment of merchandise, counting office supplies, technology products and solutions, business machines and related supplies, facilities products, and office furniture under various brands through its chain of office supply stores.
Finally, OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), ended its last trade with -3.05% loss, and closed at $2.86.
OncoGenex Pharmaceuticals Inc, declared second quarter 2015 financial results.
Financial Update and Results
- Revenue for the three and six months ended June 30, 2015 reduced to $4.0 million and $5.4 million , respectively, from $4.9 million and $16.7 million for the three and six months ended June 30, 2014 , respectively.
- Total operating expenses for the three and six months ended June 30, 2015 were $9.6 million and $16.0 million , respectively, contrast to $12.6 million and $32.2 million for the three and six months ended June 30, 2014 , respectively.
- Net loss for the three and six months ended June 30, 2015 was $6.0 million , or $0.26 per dilluted common share, and $10.5 million , or $0.46 per dilluted common share, respectively, contrast with $7.0 million , or $0.47 per diluted common share, and $15.7 million , or $1.05 per dilluted common share, respectively, for the three and six months ended June 30, 2014 .
- As of June 30, 2015 , cash, cash equivalents and short-term investments raised to $60.2 million from $47.1 million as of December 31, 2014 .
- Subsequent to June 30, 2015 , the company raised $14.7 million from the sale of common stock to Lincoln Park Capital, LLC under the terms of the share purchase agreement. As of August 13, 2015 , no further amounts remained accessible for sale under this offering program.
- Based on current expectations, the company believes that these resources, in addition to the amounts received from the sale of common stock to Lincoln Park Capital, LLC in the third quarter of 2015 will be sufficient to fund its presently planned operations late into the fourth quarter of 2016, which may comprise:
- declaration of final results of the poor prognosis subpopulation in the Phase 3 AFFINITY prostate cancer trial by the end of 2015 and final analysis for the entire study population in the second half of 2016, depending on timing of the event-driven final analysis and subject to completion and submission of the projected protocol amendment;
- declaration of final survival results in the Phase 3 ENSPIRIT lung cancer trial predictable in the second half of 2016;
- completion of enrollment in the Phase 2 Borealis-2™ bladder cancer trial predictable to occur in the third quarter of 2015;
- declaration of the Phase 2 Rainier™ pancreatic cancer trial results predictable by the end of 2015;
- declaration of the Phase 2 Spruce™ lung cancer trial results predictable in the first half of 2016;
- declaration of the Phase 2 Pacific™ prostate cancer trial preliminary results predictable in 2016; and
- completion of enrollment in the Phase 2 Cedar™ lung cancer trial predictable in 2016.
- As of August 13, 2015 , OncoGenex had 29,791,776 shares outstanding.
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
